Lakeside Holding Ltd

What they do

The company historically provided integrated cross-border ocean and air freight solutions, including consolidation, customs clearance, warehousing, and domestic ground transportation, primarily for Asian-origin goods entering the U.S. Following the February 12, 2026 transfer of its ABL Chicago operations, continuing operations now focus on pharmaceutical distribution in China through subsidiary Hupan Pharmaceutical, which supplies infusion fluids, specialty prescription drugs, and medical nutrition products to hospitals and distributors.

Revenue drivers

• Pharmaceutical distribution — Continuing operations generate revenue from selling infusion products, specialty prescription drugs, and medical nutrition products to hospitals, distributors, and healthcare providers in China.
• Cross-border logistics (discontinued) — Historical revenue came from ocean and air freight forwarding, customs clearance, warehousing, and U.S. domestic ground transportation, but these operations were transferred in February 2026 and are now reported as discontinued.
• Customer concentration — During the nine months ended March 31, 2026, four customers each accounted for over 10% of pharmaceutical revenue, indicating significant reliance on a small customer base.

Recent performance

For fiscal 2025 (ended June 30, 2025), revenue declined to $17.8 million from $18.3 million in fiscal 2024, and net loss widened to $5.2 million from $225,252. Quarterly revenue fell sharply from $9.6 million in June 2025 to $1.3 million in March 2026. Operating cash flow was negative $2.7 million for fiscal 2025. As of March 31, 2026, cash stood at $1.3 million against total assets of $17.8 million and liabilities of $4.2 million.

Strategy

Management has streamlined operations by divesting the logistics business to focus on pharmaceutical distribution, aiming to expand this segment. The company is evaluating potential opportunities in digital asset businesses, though no concrete plan has been adopted. It continues to procure products from manufacturers and distribute through agents, with an emphasis on revenue growth, gross margin, and working capital management. The company also plans to improve service quality and variety, though the current focus is on pharmaceutical operations.

Risks

• Regulatory environment in China — Pharmaceutical pricing controls, tendering processes, and reimbursement policies, including centralized procurement, can affect pricing, volumes, and margins.
• Customer concentration — Four customers accounted for over 10% of revenue each in the nine months ended March 31, 2026, so losing any could materially hurt sales.
• Accounts receivable collection — Payment terms of 60–90 days to customers, with 60-day supplier terms and potential prepayments, create cash flow risk if receivables are delayed or uncollectible.
• Delisting risk — The company received delisting notices or listing-rule failures in January and July 2026, indicating potential non-compliance with exchange requirements.

Outlook

Management expects continued focus on pharmaceutical distribution in China, with potential expansion into digital assets still under preliminary evaluation. Prior-period results have been recast to reflect the disposed logistics business as discontinued operations. The company acknowledges risks from regulatory changes, supplier relationships, and customer demand fluctuations, which could affect future revenue and margins.